Fulcrum Therapeutics, Inc. Expected to Post FY2024 Earnings of ($0.32) Per Share (NASDAQ:FULC)

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Investment analysts at Leerink Partnrs lifted their FY2024 earnings per share estimates for shares of Fulcrum Therapeutics in a note issued to investors on Thursday, September 12th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of ($0.32) per share for the year, up from their prior estimate of ($0.43). Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Fulcrum Therapeutics' current full-year earnings is ($0.48) per share. Leerink Partnrs also issued estimates for Fulcrum Therapeutics' Q4 2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($1.06) EPS.

Several other brokerages have also recently issued reports on FULC. Cantor Fitzgerald cut Fulcrum Therapeutics from an "overweight" rating to a "neutral" rating in a report on Thursday. Stifel Nicolaus cut Fulcrum Therapeutics from a "buy" rating to a "hold" rating and decreased their price objective for the company from $22.00 to $3.00 in a report on Thursday. Leerink Partners reissued a "market perform" rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Thursday. Bank of America cut Fulcrum Therapeutics from a "neutral" rating to an "underperform" rating and decreased their price objective for the company from $10.00 to $2.00 in a report on Thursday. Finally, Royal Bank of Canada cut Fulcrum Therapeutics from an "outperform" rating to a "sector perform" rating and decreased their price objective for the company from $15.00 to $4.00 in a report on Thursday. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $9.33.

Fulcrum Therapeutics Stock Down 0.3 %

Shares of FULC stock traded down $0.01 on Monday, hitting $3.17. The company had a trading volume of 2,367,128 shares, compared to its average volume of 957,885. The firm has a market cap of $197.03 million, a P/E ratio of -1.99 and a beta of 2.23. The company has a 50-day moving average price of $8.41 and a 200-day moving average price of $8.26. Fulcrum Therapeutics has a twelve month low of $2.87 and a twelve month high of $13.70.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.87 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.93. Fulcrum Therapeutics had a negative return on equity of 8.28% and a negative net margin of 3,470.05%. The company had revenue of $80.00 million during the quarter, compared to analysts' expectations of $80.00 million. During the same quarter in the previous year, the firm posted ($0.38) EPS.

Institutional Investors Weigh In On Fulcrum Therapeutics

Large investors have recently bought and sold shares of the company. National Bank of Canada FI increased its stake in Fulcrum Therapeutics by 869.6% during the 2nd quarter. National Bank of Canada FI now owns 4,460 shares of the company's stock worth $28,000 after buying an additional 4,000 shares in the last quarter. Capstone Investment Advisors LLC purchased a new stake in Fulcrum Therapeutics during the 4th quarter worth approximately $68,000. Profund Advisors LLC purchased a new stake in Fulcrum Therapeutics during the 2nd quarter worth approximately $68,000. Renaissance Technologies LLC purchased a new stake in Fulcrum Therapeutics during the 2nd quarter worth approximately $82,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Fulcrum Therapeutics by 66.7% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,916 shares of the company's stock worth $112,000 after purchasing an additional 4,766 shares during the last quarter. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.